natgillin/translations-raw huggingface dataset:
Rebif is given by injection under the skin (subcutaneously) using a pre-filled pen called “RebiDose”.
Zdravilo Rebif se daje z injiciranjem pod kožo (subkutano), z uporabo napolnjenega injekcijskega peresnika, ki se imenuje »RebiDose«.
Rebif is given by injection under the skin (subcutaneously).
Zdravilo Rebif se daje z injiciranjem pod kožo (subkutano).
Rebif is not recommended for use in children below 2 years of age.
Zdravilo Rebif se ne priporoča pri otrocih, starih manj kot 2 leti.
Rebif is used to treat patients with relapsing multiple sclerosis (MS).
Zdravilo Rebif se uporablja za zdravljenje bolnikov z multiplo sklerozo (MS) z zagoni.
Rebif must also not be used in patients who are suffering from severe depression or having thoughts about committing suicide.
Zdravilo Rebif se prav tako ne sme uporabljati pri bolnikih, ki trpijo za hudo depresijo ali imajo samomorilne misli.
Rebif must not be used in people who are hypersensitive (allergic) to natural or recombinant interferon beta, or any of the other ingredients.
Zdravila Rebif ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) naravni ali rekombinantni interferon beta ali katero koli drugo sestavino zdravila.
Rebif must then be returned to the refrigerator and used before the expiry date.
Nato morate zdravilo Rebif postaviti nazaj v hladilnik in ga uporabiti do datuma izteka roka uporabnosti.
Rebif should only be used under the supervision of your doctor.
Zdravilo Rebif se sme uporabljati samo pod nadzorom zdravnika.
Rebif solution is clear to opalescent.
Rebif je bistra do opalescentna raztopina.
Rebif treatment must not be started during pregnancy.
Zdravljenje z zdravilom Rebif se ne sme uvesti med nosečnostjo.
Rebif treatment should be started by a doctor who has experience in the management of MS.
Zdravljenje z zdravilom Rebif mora uvesti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
Rebif was more effective than placebo in reducing the number of relapses in relapsing MS.
Zdravilo Rebif je bilo pri zmanjševanju števila zagonov pri multipli sklerozi z zagoni učinkovitejše od placeba.
Rebif, like other interferons beta, has a potential for causing severe liver injury including acute hepatic failure (see section 4.8).
Zdravilo Rebif ima, tako kot drugi interferoni, potencial za povzročanje hudih jetrnih poškodb, vključno z jetrno odpovedjo (glejte poglavje 4.8).
Rebif’s effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS) that is not relapsing.
Učinkovitost zdravila Rebif ni bila ugotovljena pri bolnikih s sekundarno progresivno multiplo sklerozo (vrsto multiple skleroze, ki nastopi po multipli sklerozi z zagoni), ki se ne pojavlja v zagonih.
RebiSmart is programmed to guide you through the entire initiation process and automatically increases the dose during the initiation period.
Pripomoček RebiSmart je programiran tako, da vas vodi skozi celotni začetni postopek in samodejno povečuje odmerek v začetnem obdobju.
Rebound, as defined by an increase in blood phenylalanine levels above pre-treatment levels, may occur upon cessation of treatment.
Po prekinitvi zdravljenja lahko pride do pojava povratnega učinka, ki je definiran kot povečanje ravni fenilalanina v krvi nad raven, ki je bila ugotovljena pred začetkom zdravljenja.
Rebounder
Ponovitev
Rebounders Never suppressed subjects
Bolniki s ponovitvijo Bolniki, pri katerih nikoli ni bilo odziva
Recap the pen after use to protect from light.
Zapirajte peresnik s pokrovčkom za zagotovitev zaščite pred svetlobo.
Recapping is not required.
Pokrovčka ni treba ponovno pritrditi.
receiving chemotherapy, radiation treatment or immunosuppression.
osebe, ki prejemajo kemo-, radio- ali imunosupresivno terapijo.
receiving concomitant treatment
sočasno prejemajo zdravilo
receiving concomitant treatment
učinke, ki so povezani z
receiving digoxin should
Bolnike, ki prejemajo
receiving prednisone and
prednizon in zdravilo
receiving ≥2 prior MS therapies
2 predhodni zdravljenji MS
recent (< 10 days) prolonged and vigorous external heart massage
nedavna (< 10 dni) podaljšana in intenzivna zunanja masaža srca,
Recent (within 3 months) ischaemic stroke
Ishemični cerebrovaskularni insult v zadnjih 3 mesecih
Recent administration (within 3 days) of thrombolytic therapy
Trombolitično zdravljenje v zadnjih 3 dnevih
Recent administration (within 7 days) of aspirin or other platelet inhibitors
Uporaba aspirina ali drugih zaviralcev agregacije trombocitov v zadnjih 7 dnevih
Recent administration (within 7 days) of oral anticoagulants
Uporaba peroralnih antikoagulantov v zadnjih 7 dnevih
Recent biopsy, major trauma
nedavna biopsija, večja poškodba
Recent bleeding (e.g. in brain, stomach/intestine, eye, lung)
pred kratkim krvavitev (npr. v možganih, želodcu, črevesu, očeh, pljučih)
Recent bleeding (e.g. intracranial, gastrointestinal, intraocular, pulmonary)
nedavna krvavitev (npr. intrakranialna, gastrointestinalna, intraokularna, pljučna)
recent bleeding in your brain (intracranial or intracerebral bleeding)
nedavna krvavitev v vaših možganih (intrakranialna ali intracerebralna krvavitev),
Recent cerebrovascular accident, stroke, or intracerebral surgery
nedavni cerebrovaskularni insult, kap ali možganska operacija
recent completed neurosurgical or ophthalmological procedures, concomitant use of medicinal products affecting haemostasis.
nedavna nevrološka ali očesna operacija, sočasna uporaba zdravil, ki vplivajo na hemostazo.
Recent data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or gene-specific.
Novejši podatki kažejo, da lahko estrogenski receptor regulira gensko ekspresijo po vsaj dveh različnih poteh, ki sta specifični za ligand, tkivo in/ali gen.
recent gastrointestinal or genitourinary bleeding (within 10 days)
nedavna krvavitev v prebavila, sečila ali spolovila (v zadnjih 10 dneh),
Recent gastrointestinal or genitourinary bleeding (within the past 10 days)
nedavna krvavitev iz prebavil, rodil ali sečil (v preteklih 10 dneh),
recent history of inflammation of the membrane that forms the lining of the abdominal (tummy) cavity (peritonitis) low levels of albumin (a protein) in your blood
nedavno vnetje membrane, ki oblikuje oblogo abdominalne (trebušne) votline (peritonitis), nizke ravni albumina (beljakovine) v krvi.
Recent history of peritonitis in peritoneal dialysis patients
peritonitisom v novejši anamnezi pri bolnikih na peritonealni dializi, z albuminom v serumu <30 g/l.
recent history of stroke or myocardial infarction (within the last 6 months), unstable angina and known hereditary retinal degenerative disorders such as retinitis pigmentosa.
ki so doživeli možgansko kap ali miokardni infarkt v zadnjih šestih mesecih, ki imajo nestabilno angino pektoris in znano dedno degenerativno bolezen mrežnice (retinitis pigmentosa).
recent ischemic stroke,
nedavna ishemična možganska kap,
recent major stomach or bowel surgery
nedavno veliko operacijo želodca ali črevesja,
Recent major surgery
nedavni večji operativni poseg
Recent major surgery
pred kratkim večji operativni poseg
Recent marketing of the veterinary medicinal product
Nedavnega začeteka trženja zdravila za uporabo v veterinarski medicini
recent myocardial infarction
nedaven miokardni infarkt
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
recent myocardial infarction shock
nedavni miokardni infarkt, šok.
recent myocardial infarction,
nedaven miokardni infarkt,
recent myocardial infarction,
nedavni miokardni infarkt,
recent myocardial infarction, shock;
nedavni miokardni infarkt, šok,
Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, theinitiation of leflunomide treatment has to be carefully considered regarding these benefit/risk aspects.
Nedavno ali sočasno zdravljenje s hepatotoksičnimi ali hematotoksičnimi imunomodulirajočimi antirevmatičnimi zdravili (npr. z metotreksatom) lahko poveča tveganje za resne neželene učinke; zato je treba pri uvedbi leflunomida skrbno pretehtati korist in tveganje tega zdravljenja.
Recent or ongoing clinically significant gastrointestinal disorder
Nedavne ali prisotne klinično pomembne bolezni prebavil
recent or recurrent bleeding from the stomach or intestines (e.g. a stomach ulcer or colon polyps) body weight of less than 60 kg.
nedavna ali ponovna krvavitev iz želodca ali črevesja (npr. želodčni ulkus ali polipi debelega črevesja) telesna masa nižja od 60 kg.
Recent puncture of large vessels or organ biopsy
nedavna punkcija večjih žil ali biopsija organov
Recent puncture of large vessels or organs
pred kratkim punkcijo večjih žil ali organov
Recent stroke, accident or surgery involving the brain
pred nedavnim kap, nesrečo ali operacijo možganov
recent surgery (including dental work)
nedavne operacije (vključno z zobozdravstvenimi posegi)
recent surgery (including dental work, ask your dentist about this)
nedavne operacije (vključno z zobozdravstvenimi posegi, o tem se posvetujte z zobozdravnikom)
recent surgery (including some dental procedures)
nedavni kirurški poseg (vključno z nekaterimi zobozdravstvenimi posegi)
recent surgery on the brain, spine or eye
nedavno operacijo na možganih, hrbtenici ali očeh.
recent surgery on the brain, spine or eye
nedavno operacijo na možganih, hrbtenici ali očeh;
Recent trauma to the head or cranium
nedavna poškodba glave ali lobanje,
Recent treatment with medicinal products known to prolong the QTc interval that may still be circulating at the time that Eurartesim is commenced (e.g. mefloquine, halofantrine, lumefantrine, chloroquine, quinine and other antimalarial medicinal products) taking into account their elimination half-life.
Nedavno zdravljenje z zdravili, za katera je znano, da podaljšujejo interval QTc, ki lahko še vedno cirkulirajo v času uvedbe zdravila Eurartesim (npr. meflokin, halofantrin, lumefantrin, klorokinin, kinin in drugi antimalariki), ob upoštevanju njihovega razpolovnega časa izločanja.
Recent use of these medicines might increase the risk of Aerivio Spiromax affecting your adrenal glands.
Če ste ta zdravila uporabljali pred kratkim, se lahko poveča tveganje, da bi zdravilo Aerivio Spiromax vplivalo na delovanje nadledvične žleze.
Recent use of these medicines might increase the risk of Aerivio Spiromax affecting your adrenal glands.
Če ste ta zdravila uporabljali pred kratkim, se lahko poveča tveganje, da bi zdravilo Airexar Spiromax vplivalo na delovanje nadledvične žleze.
recently a brief shortage of blood supply to a part of the brain within the last six months bleeding in the gut or lung within the past three months.
nedavno kratko poslabšanje pretoka krvi skozi del možganov v zadnjih šestih mesecih krvavitev v črevo ali pljuča v zadnjih treh mesecih.
recently had a myocardial infarction (heart attack).
so nedavno doživeli miokardni infarkt (srčni napad).
recently had a stroke within the last 6 months.
te v zadnjih 6 mesecih preboleli možgansko kap.
recently suffered a head injury or brain disease
nedavnih poškodb glave ali bolezni možganov,
Recently treated animals should not be handled until the application site is dry
Ne dotikajte se nedavno zdravljene živali, dokler se mesto nanosa ne posuši.
Recently treated animals should not be handled until the application site is dry.
Ne dotikajte se nedavno zdravljene živali, dokler se mesto nanosa ne posuši.
Recently treated dogs should not be allowed to sleep in the same bed as their owners, especially children.
Pravkar zdravljeni živali ne dovolite, da spi v isti postelji kot lastnik, še posebej velja to za otroke.
Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphatase (cGMP) production, which then activates a protein kinase and increases the production of HbF.
V zadnjem času se je pokazalo, da je hidroksikarbamid povezan z nastajanjem dušikovega oksida, kar kaže na to, da dušikov oksid spodbuja proizvodnjo cikličnega gvanozin monofosfata (cGMP), ki nato aktivira proteinsko kinazo in zviša proizvodnjo HbF.
receptor antagonist.
antagonistom histaminskih
Receptors for somatostatin can be found in high amounts on tumour cells, including tumours of the pituitary gland which cause Cushing’s disease and acromegaly.
Receptorji za somatostatin se v velikem številu pojavljajo na tumorskih celicah, vključno na tumorjih hipofize, ki povzročajo Cushingovo bolezen in akromegalijo.
recFSH 150 IU
(rek)FSH 150 i.e.
recFSH 200 IU
(rek)FSH 200 i.e.
recFSH 300 IU
(rek)FSH 300 i.e.
Recheck the prescribed medication amount.
Ponovno preverite predpisano količino zdravila.
Recipients of allogeneic PBPCs mobilised with filgrastim
Prejemniki alogenskih matičnih celic iz periferne krvi izplavljenih s filgrastimom.
Recocam 20 mg/ml solution for injection for cattle, pigs and horses
Recocam 20 mg/ml, raztopina za injiciranje za govedo, prašiče in konje
Recocam 20 mg/ml solution for injection for cattle, pigs and horses meloxicam
Recocam 20 mg/ml, raztopina za injiciranje za govedo, prašiče in konje meloksikam
Recocam 20 mg/ml solution for injection for cattle, pigs and horses meloxicam
Recocam 20 mg/ml, raztopina za injiciranje za govedo, prašiče in konje. meloksikam
Recocam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Recocam vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSPVZ).
Recocam is a ‘generic’ medicine which means that Recocam is similar to a ‘reference veterinary medicine’ already authorised in the EU (Metacam).
Zdravilo Recocam je generično zdravilo, kar pomeni, da je podobno referenčnemu veterinarskemu zdravilu, ki je že odobreno v EU (zdravilu Metacam).
Recocam is given as a single injection of 0.6 mg per kg body weight into the horse’s vein.
Zdravilo Recocam se injicira v enem 0,6-miligramskem odmerku na kilogram telesne mase v konjevo veno.
Recocam is ‘bioequivalent’ to the reference medicine which means that it is equivalent to Metacam in the way it is absorbed and used by the body.
Zdravilo Recocam je biološko enakovredno referenčnemu zdravilu, kar pomeni, da je enakovredno zdravilu Metacam, in sicer glede na to, kako ga telo absorbira in uporablja.
Recognition and treatment of severe immune-mediated reaction, including anaphylaxis.
prepoznava in zdravljenje resnih reakcij, povezanih z imunostjo, vključno z anafilaksijo,
Recognition of signs and symptoms of severe hypoglycaemia and the appropriate actions to take
Prepoznava znakov in simptomov hude hipoglikemije in ustrezno ukrepanje.
Recognition of signs and symptoms of under or no delivery of insulin and the appropriate actions to take
Prepoznava znakov in simptomov nezadostnega dovajanja ali nedovajanja insulina in ustrezno ukrepanje.
Recombinant
MEč*/ vialo
recombinant
rekombinantni
Recombinant cholera toxin B subunit (rCTB) 1 mg
Rekombinantna podenota toksina kolera B (rCTB) 1 mg
Recombinant cholera toxin B subunit (rCTB) 1 mg
Vibrio cholerae O1 Ogawa, klasični biotip (inaktiviran s 31,25 x 109 bakterij* formalinom) rekombinantno podenoto toksina kolera B (rCTB) 1 mg
Recombinant cholera toxin B subunit (rCTB) 1 mg.
1 mg rekombinantne podenote toksina kolera B (rCTB).
Recombinant cholera toxin B subunit (rCTB) 1 mg.
Rekombinantno podenoto toksina kolera B (rCTB).
Recombinant coagulation factor VIII (octocog alfa) Intravenous use.
rekombinantni koagulacijski faktor VIII (oktokog alfa) Intravenska uporaba.
Recombinant FSH is biochemically very similar to urinary human FSH and is distributed, metabolised, and excreted in the same way.
Rekombinantni FSH je biokemično zelo podoben humanemu urinskemu FSH in se porazdeli, presnovi in izloči na enak način.
recombinant human antithrombin produced in the milk of transgenic goats by recombinant DNA technology (rDNA).
Rekombinantni humani antitrombin se proizvaja s tehnologijo rekombinantne DNA (rDNA) v mleku transgenskih koz.
recombinant human follicle stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
rekombinantni humani folikle stimulirajoči hormon (r-hFSH), pridobljen iz celic jajčnika kitajskega hrčka (Chinese Hamster Ovary – CHO) z uporabo tehnologije rekombinantne DNK.
Recombinant human hyaluronidase (rHuPH20)
Rekombinantna humana hialuronidaza (rHuPH20)
Recombinant human hyaluronidase (rHuPH20) vial
Viala rekombinantne humane hialuronidaze (rHuPH20)
Recombinant human hyaluronidase (rHuPH20) vial Sodium chloride
Viala rekombinantne humane hialuronidaze (rHuPH20) natrijev klorid
Recombinant human hyaluronidase is a purified glycoprotein of 447 amino acids produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Rekombinantna humana hialuronidaza je prečiščen glikoprotein iz 447 aminokislin, pridobljen iz celic jajčnika kitajskega hrčka (CHO) s tehnologijo rekombinantne DNA.
Recombinant humanized IgG1 anti-Tac antibody produced in a murine NSO myeloma cell line using a glutamine synthetase (GS) expression system (NS_GSO) by recombinant DNA technology.
Rekombinantno humanizirano IgG1 anti-Tac protitelo, pridobljeno s tehnologijo rekombinantne DNA iz celične kulture mieloma NSO glodalcev s pomočjo ekspresijskega sistema glutamin sintetaze (NS_GSO, glutamin synthetase expression system).
Recombinant interferon beta-1b* 250 microgram (8.0 million IU) per ml when reconstituted.
rekombinantni interferon beta-1b,* 250 mikrogramov (8,0 milijonov i.e.) na mililiter po rekonstituciji
recombinant murine/human chimeric monoclonal antibody directed against the interleukin-2 receptor -chain (CD25 antigen) produced in a mouse myeloma cell line by recombinant DNA technology.
rekombinantno glodalsko/človeško himerno monoklonalno protitelo, usmerjeno proti  verigi receptorja za interlevkin-2 (antigen CD25), ki ga s tehnologijo rekombinantne DNA izdelujejo v kulturi mielomskih celic miši.
Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3
rekombinantna fuzijska beljakovina NHBA iz Neisseria meningitidis skupine B 1, 2, 3
Recombinant Neisseria meningitidis group B NHBA/NadA/fHbp proteins
rekombinantne beljakovine NHBA/NadA/fHbp iz Neisseria meningitidis skupine B
Recombinant Omega interferon of feline origin 10 MU*/ vial
Rekombinant omega interferon mačjega izvora 10 ME* / vialo
Recombinant Omega interferon of feline origin 10 MU*/ vial
Rekombinantni omega interferon mačjega izvora 10 ME* / vialo
Recombinant Omega interferon of feline origin 10 MU*/ vial
rekombinantni omega interferon mačjega izvora 10 ME*/ vialo
Recombinant Omega interferon of feline origin 5 MU*/ vial
Rekombinantni omega interferon mačjega izvora 5 ME* / vialo
Recombinant Omega interferon of feline origin 5 MU*/ vial
rekombinantni omega interferon mačjega izvora 5 ME*/ vialo
Recombinant Protein Q from L. infantum MON-1
Rekombinantni protein Q iz L. infantum MON-1
Recombinant Protein Q from Leishmania infantum MON-1 ≥ 36.7 ELISA Units (EU)*
Rekombinantni protein Q iz Leishmania infantum MON-1 ≥ 36,7 enot ELISA (EU)
Recombinant Protein Q from Leishmania infantum MON-1: ≥ 36.7 ELISA units (EU)*
Rekombinantni protein Q iz Leishmania infantum MON-1 ≥ 36,7 enot ELISA (EU)
Recombinant Type D Pasteurella multocida toxin (PMTr): ....................................≥ 1 MED63
Rekombinantni toksin bakterije Pasteurella multocida tipa D (PMTr): ..................≥ 1 MED63
Recombinant viruses showing ≥ 3- fold resistance to tipranavir grow at less than 1% of the rate detected for wild type HIV-1 in the same conditions.
Število rekombinantnih virusov, ki so ≥ 3-kratno odporni proti tipranavirju, naraščajo s stopnjo, ki znaša v enakih razmerah manj kot 1% stopnje pri virusu divjega tipa.
recommendation can be
odmerjanje.
Recommendation concerning co- administration
Priporočilo glede sočasne uporabe
Recommendation concerning co- administration with ZEPATIER
Priporočilo glede sočasne uporabe z zdravilom ZEPATIER
Recommendation concerning co-administration with 245 mg tenofovir disoproxil (as fumarate)
Priporočilo glede sočasne uporabe z 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata)
Recommendation concerning co-administration with cobicistat 150 mg and atazanavir or darunavir
Priporočilo glede sočasne uporabe s kobicistatom 150 mg in atazanavirjem ali darunavirjem
Recommendation concerning co-administration with efavirenz
efavirenzem potrebna sočasna
Recommendation concerning co-administration with efavirenz
indinavirjem/ritonavirjem
Recommendation concerning co-administration with efavirenz
jemanjem efavirenza in
Recommendation concerning co-administration with efavirenz
Pri sočasni uporabi efavirenza z
Recommendation concerning co-administration with efavirenz
Pri sočasni uporabi z efavirenzem
Recommendation concerning co-administration with efavirenz
Sočasna uporaba simeprevirja z
Recommendation concerning co-administration with Truvada (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg)
Priporočilo glede sočasne uporabe z zdravilom Truvada (emtricitabin 200 mg, dizoproksiltenofovirijev fumarat 300 mg)
Recommendation for a 3-hour on-site observation period post injection
Priporočilo za 3-urno opazovanje na mestu po injiciranju
Recommendation for appropriate monitoring until the event resolves if an event should occur
Priporočilo za ustrezno spremljanje bolnikov, dokler se, v primeru pojava učinkov, učinki ne izboljšajo
Recommendation for co- administration
Priporočila za sočasno uporabo
Recommendation for informing patients that for the remainder of the day of the injection, they should not drive or operate machinery, should be vigilant for signs and symptoms of a post injection syndrome event, and should be able to obtain assistance if needed
Priporočilo o obvestilu bolnikom, da preostanek dneva po injiciranju ne vozijo in ne upravljajo s stroji, da morajo biti pozorni na znake in simptome sindroma po injiciranju ter da morajo imeti možnost po potrebi poiskati pomoč
Recommendation for kidney function measurement
Priporočilo za merjenje ledvičnega delovanja
Recommendation for overnight monitoring after the first dose (or if the first dose monitoring applies during treatment re-initiation)
Priporočila za spremljanje bolnika preko noči po prejemu prvega odmerka (ali v primeru ponovitve spremljanja kot po prejemu prvega odmerka pri ponovni uvedbi zdravljenja).
Recommendation for patients not to drive while receiving BLINCYTO
Priporočilo za bolnike, da medtem, ko prejemajo zdravilo BLINCYTO, ne vozijo.
Recommendation for patients not to drive while receiving BLINCYTO and to contact immediately the treating physician if they experience neurological symptoms
Priporočilo za bolnike, da medtem ko prejemajo zdravilo BLINCYTO, ne vozijo in takoj kontaktirajo zdravnika, če se jim pojavijo nevrološki simptomi.
Recommendation for patients not to drive while receiving BLINCYTO and to contact immediately the treating physician/nurse if they experience neurological symptoms
Priporočilo za bolnike, da medtem, ko prejemajo zdravilo BLINCYTO, ne vozijo in takoj kontaktirajo zdravnika, če se jim pojavijo nevrološki simptomi.
Recommendation regarding accidental exposure of IMLYGIC to HCPs:
Priporočilo zdravstvenim delavcem glede nenamerne izpostavljenosti zdravilu IMLYGIC.
Recommendation regarding the accidental transmission of IMLYGIC from patient to close contacts or HCPs:
Priporočilo glede nenamernega prenosa zdravila IMLYGIC z bolnika na osebe, ki so v tesnem stiku z bolnikom, ali zdravstvene delavce.